1. Home
  2. FAX vs PCRX Comparison

FAX vs PCRX Comparison

Compare FAX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAX
  • PCRX
  • Stock Information
  • Founded
  • FAX 1986
  • PCRX 2006
  • Country
  • FAX United States
  • PCRX United States
  • Employees
  • FAX N/A
  • PCRX N/A
  • Industry
  • FAX Investment Managers
  • PCRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAX Finance
  • PCRX Health Care
  • Exchange
  • FAX Nasdaq
  • PCRX Nasdaq
  • Market Cap
  • FAX 654.7M
  • PCRX 1.2B
  • IPO Year
  • FAX N/A
  • PCRX 2011
  • Fundamental
  • Price
  • FAX $15.99
  • PCRX $22.90
  • Analyst Decision
  • FAX
  • PCRX Buy
  • Analyst Count
  • FAX 0
  • PCRX 8
  • Target Price
  • FAX N/A
  • PCRX $28.38
  • AVG Volume (30 Days)
  • FAX 833.6K
  • PCRX 525.8K
  • Earning Date
  • FAX 01-01-0001
  • PCRX 07-29-2025
  • Dividend Yield
  • FAX 12.09%
  • PCRX N/A
  • EPS Growth
  • FAX N/A
  • PCRX N/A
  • EPS
  • FAX N/A
  • PCRX N/A
  • Revenue
  • FAX N/A
  • PCRX $702,772,000.00
  • Revenue This Year
  • FAX N/A
  • PCRX $7.92
  • Revenue Next Year
  • FAX N/A
  • PCRX $11.02
  • P/E Ratio
  • FAX N/A
  • PCRX N/A
  • Revenue Growth
  • FAX N/A
  • PCRX 3.08
  • 52 Week Low
  • FAX $2.33
  • PCRX $11.16
  • 52 Week High
  • FAX $2.84
  • PCRX $27.64
  • Technical
  • Relative Strength Index (RSI)
  • FAX 57.17
  • PCRX 35.82
  • Support Level
  • FAX $15.93
  • PCRX $22.82
  • Resistance Level
  • FAX $16.45
  • PCRX $23.83
  • Average True Range (ATR)
  • FAX 0.26
  • PCRX 0.74
  • MACD
  • FAX -0.00
  • PCRX -0.02
  • Stochastic Oscillator
  • FAX 59.14
  • PCRX 6.22

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: